Overview

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

Status:
Completed
Trial end date:
2018-09-26
Target enrollment:
Participant gender:
Summary
A Phase 1, placebo-controlled, two part study with either single dose or multiple increasing oral dose to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTX-6970 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Centrexion Therapeutics